A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome

Trial Profile

A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2018

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Dumping syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 25 Apr 2018 Primary endpoint (Response Rate in Plasma Glucose Level) has been met, according to results published in the Alimentary Pharmacology and Therapeutics.
    • 25 Apr 2018 Results (n=43) assessing the efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome, were published in the Alimentary Pharmacology and Therapeutics.
    • 11 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top